In this episode of 'Honestly with Bari Weiss,' Sam Altman, CEO of OpenAI, discusses his contentious relationship with Elon Musk over the direction of artificial intelligence (AI) technology. The conversation covers the rapid evolution of AI, ethical considerations regarding its governance, and the implications of a potential AI arms race between the U.S. and China. Altman reflects on OpenAI's transition from a nonprofit to a hybrid model, emphasizing the importance of funding for continued progress while highlighting the need for transparency and responsible AI development.

In this episode, Julian Lennon discusses personal health experiences, touching on a cancer scare and the importance of self-care and mental health. The conversation shifts to concerns about virus research and the balance of good and evil in the world. Lennon shares insights about his life in Monaco, cultural experiences in Italy, and his transition from London to LA while navigating celebrity culture. He emphasizes the significance of meaningful relationships, his photography journey, and the establishment of the White Feather Foundation for indigenous rights. The episode concludes with reflections on reality, perception, and philosophical discussions about free will.

In this episode, the hosts recap Week 15 of fantasy football, discussing standout performances, disappointing results, and injury updates as fantasy managers navigate the playoff landscape. They analyze the mixed results of players like Marvin Harrison Jr. and the motivations behind certain performances, particularly financial incentives tied to contracts. Key players such as Mike Evans, Alvin Kamara, and Derek Henry are evaluated for their contributions and challenges during the week, while the impact of injuries is emphasized. The episode ultimately provides insights and strategies for managing fantasy teams effectively during this critical season.

This episode features Stephen J. Dubner in conversation with Ezekiel Emanuel about the transformative impacts of GLP-1 drugs like Ozempic, developed for type 2 diabetes and obesity. The discussion covers the drug's effectiveness for weight loss, insurers' challenges regarding coverage, and ethical implications on access. They also explore the U.S. healthcare system's inefficiencies, particularly its focus on short-term costs instead of long-term investments. The conversation extends to broader healthcare topics, including AI's potential in medicine and the rising incidence of certain cancers among younger populations, emphasizing the need for lifestyle changes and better healthcare equity.